All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
3 warning events since 2017; the latest 2022-03-25.
From the record
BeOne Medicines Ltd.'s filings since 2017 show 3 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 2 times, the latest 2017-06-12); an auditor change (8-K item 4.01, the latest 2022-03-25) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+157.6% a year over 10 filed years; profitable in 1 of 10.
From the record
BeOne Medicines Ltd.'s 10 filed years say what it did: revenue went from $1 million in fiscal 2016 to $5.3 billion in fiscal 2025, up 157.6% a year; it rose in 7 of 9 years; the deepest fall was 28% from fiscal 2019 to fiscal 2020; net income was positive in 1 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 7.7/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: BeOne Medicines Ltd.'s shareholder treatment is put at 7.7 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 23% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE 7%: 7¢ of profit per shareholder dollar. Leverage 47%: owes 47¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, BeOne Medicines Ltd. earned about 7 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 57 cents per dollar of everything the company owns. Leverage: it owed about 47 cents per dollar of assets, and net share issuance: its share count grew 7.8% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 16% of 315 in its family; net margin 5.4%.
From the record
BeOne Medicines Ltd.'s standing among 315 graded names in its industry family: revenue of $5.3 billion in fiscal 2025 ranks in the top 6% by size; a net margin of 5.4% ranks in the top 20%; revenue growth of 55.7% a year over the last 3 filed years ranks in the top 22% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 39% of 315 in its family for leadership; chief executive since 2016.
From the record
BeOne Medicines Ltd.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Oyler, John (Chief Executive Officer, as filed), filing under that title since 2016-02-02, 10.8 years (top 15% of its family); the 18 officers and directors filing in the last fifteen months have been on the record a median of 5.2 years (bottom 39%); 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 18 people in charge now (top 42%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 34% of 273 in its family for room to expand.
From the record
BeOne Medicines Ltd.'s room to grow, from the newest filed statements (fiscal 2025): cash of $4.5 billion against debt of $962 million leaves 43.8% of its assets as net cash, top 36% of its family; cash from operations less capital spending is 17.6% of revenue (top 16%); a gross margin of 87.5% (top 22%); research spending of 40.2% of revenue (bottom 38%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 46% of 306 in its family for growth drivers.
From the record
BeOne Medicines Ltd.'s growth drivers, from the filed years to fiscal 2025: revenue grew 55.7% a year over the last three filed years against 157.6% over all 10, slowing (bottom 3% of its family); the newest year grew 40.3% (top 29%); research spending grew 9.4% a year (top 40%); capital spending grew -17% a year (bottom 48%) (its annual reports). BeOne Medicines Ltd. reported 2 product lines in fiscal 2025: Product at $5.3 billion (99%), Collaboration at $61 million (1%); 2 of 2 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 37% of 233 in its family for expectations against reality.
From the record
BeOne Medicines Ltd.'s newest year against its own record: revenue of $5.3 billion in fiscal 2025 came in 14.5% below the $6.2 billion its prior three years' pace pointed to (bottom 36% of its family); net income of $287 million against a prior three-year average of $1.2 billion (top 13%); a net margin of 5.4% against -64.8% before (top 35%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made